Source-backed trade-policy analysis for import-scope decisions. Start from a product line, origin, supplier, or case, then move from public record to operating posture.
Beijing's June 22 export control listing shows the new U.S.-China pattern: tariff stabilization continues while strategic-control escalation intensifies.
BIS penalized Bosch $36 million for EAR99 sensors and automotive software captured by the Huawei FDPR through U.S.-derived production and testing equipment.
India's 18% rate was promised under the IEEPA reciprocal regime the Supreme Court struck down, and no durable Section 301 or 122 authority yet carries it.
The Hormuz toll is not a tariff. The real exposure sits at the import border, in Section 122 and any legally issued Section 232 or 301 measures, not the strait.
The U.S. built the IPEF supply-chain network and led two of its three bodies at launch, but the public record did not put it in the May 26 Hormuz session.
Hormuz hands the administration a supply-chain-security story, but helium sits outside the current Section 232 tariff architecture. The docket the shock reinforces is Section 301, not 232.
Section 301 supplies the tariff power IEEPA lacked. The German drug-pricing case is weak instead on statutory fit and the causal chain to U.S. commerce.
Staiger's WTO reform case preserves MFN and consensus, but U.S. tariff practice after IEEPA now runs through Section 122, 232, and 301 tools that do not.
Not yet a Section 301 tariff. USTR has opened the drug-pricing record, but the live duty exposure remains Proclamation 11020's Section 232 regime.
Downstream payors want the CIT to reserve identifiable tariff amounts inside CAPE while a parallel Court of Federal Claims case tests who owns them.